,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000HeygU2AR'}, 'Id': 'a0POZ00000HeygU2AR', 'Event_Date__c': '2013-11-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqUEQA0'}, 'change': None}]",Nov 2013,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2014', 'fs': 'Feb 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000HeygV2AR'}, 'Id': 'a0POZ00000HeygV2AR', 'Event_Date__c': '2014-02-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2014', 'Status_History__c': 'a132P000000AqaQQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2014', 'fs': 'Feb 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 February 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 February 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000HeygW2AR'}, 'Id': 'a0POZ00000HeygW2AR', 'Event_Date__c': '2014-02-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 February 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Feb 2014', 'Status_History__c': 'a132P000000AqbHQAS'}, 'change': None}, {'Summary': {'s': 'The Subcommittee &#39;recommended investigating funding pneumococcal vaccination further and in particular assessing vaccination with PCV 13 followed by PPV23 either for universal vaccination of all people over the age of 65 or for patients considered to be at high risk of pneumococcal infection.&#39;', 'fs': 'The Subcommittee &#39;recommended investigating funding pneumococcal vaccination further and in particular assessing vaccination with PCV 13 followed by PPV23 either for universal vaccination of all people over the age of 65 or for patients considered to be at high risk of pneumococcal infection.&#39;', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">Immunisation Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">Immunisation Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2015', 'fs': 'Feb 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Immunisation Subcommittee at meeting Wednesday 18 February 2015.', 'fs': 'Clinical advice received from Immunisation Subcommittee at meeting Wednesday 18 February 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000HeygZ2AR'}, 'Id': 'a0POZ00000HeygZ2AR', 'Event_Date__c': '2015-02-18', 'Event_Description__c': 'Clinical advice received from Immunisation Subcommittee at meeting Wednesday 18 February 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">Immunisation Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Subcommittee &#39;recommended investigating funding pneumococcal vaccination further and in particular assessing vaccination with PCV 13 followed by PPV23 either for universal vaccination of all people over the age of 65 or for patients considered to be at high risk of pneumococcal infection.&#39;', 'Formatted_Date__c': 'Feb 2015', 'Status_History__c': 'a132P000000AqsPQAS'}, 'change': None}, {'Summary': {'s': 'PTAC recommended the application be declined.', 'fs': 'PTAC recommended the application be declined.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2015', 'fs': 'Aug 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heyga2AB'}, 'Id': 'a0POZ00000Heyga2AB', 'Event_Date__c': '2015-08-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 August 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'PTAC recommended the application be declined.', 'Formatted_Date__c': 'Aug 2015', 'Status_History__c': 'a132P000000AqyJQAS'}, 'change': None}, {'Summary': {'s': 'Updated information received from supplier.', 'fs': 'Updated information received from supplier.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2020', 'fs': 'Nov 2020', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygb2AB'}, 'Id': 'a0POZ00000Heygb2AB', 'Event_Date__c': '2020-11-30', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'Updated information received from supplier.', 'Formatted_Date__c': 'Nov 2020', 'Status_History__c': 'a132P000000COcyQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2020', 'fs': 'Nov 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygc2AB'}, 'Id': 'a0POZ00000Heygc2AB', 'Event_Date__c': '2020-11-30', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2020', 'Status_History__c': 'a132P000000COd3QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 25 March 2021', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 25 March 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygd2AB'}, 'Id': 'a0POZ00000Heygd2AB', 'Event_Date__c': '2021-03-12', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 25 March 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000Cg8nQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee <b>recommended</b> that p<span style=""color: black;"">neumococcal polysaccharide vaccine (PPV23) </span>for the <span style=""color: black;"">immunisation of all people 65 years of age and over</span> be <b>declined</b>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered that further advice is required from the Immunisation Subcommittee regarding: </p><p class=""ql-indent-1"">1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The possible risks and benefits of funding the PPV23 for Māori; and additionally for Pacific people and others facing health disparities as a result of underlying disadvantage who are also under 65 years of age, and finally for those with comorbidities such as COPD or rheumatic heart disease; </p><p class=""ql-indent-1"">1.2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The possible risks and benefits of funding the PPV23 for the general population under 65 years of age and whether there were any age groups that would potentially benefit most from immunisation with PPV23; </p><p class=""ql-indent-1"">1.2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Whether repeat dosing would be required for an older patient population due to immunosenescence;</p><p class=""ql-indent-1"">1.2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The relevance of herd immunity to pneumococcal infection; </p><p class=""ql-indent-1"">1.2.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The relevance of the current special groups listed in the Special Authority, and whether these should be revisited.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee <b>recommended</b> that p<span style=""color: black;"">neumococcal polysaccharide vaccine (PPV23) </span>for the <span style=""color: black;"">immunisation of all people 65 years of age and over</span> be <b>declined</b>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered that further advice is required from the Immunisation Subcommittee regarding: </p><p class=""ql-indent-1"">1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The possible risks and benefits of funding the PPV23 for Māori; and additionally for Pacific people and others facing health disparities as a result of underlying disadvantage who are also under 65 years of age, and finally for those with comorbidities such as COPD or rheumatic heart disease; </p><p class=""ql-indent-1"">1.2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The possible risks and benefits of funding the PPV23 for the general population under 65 years of age and whether there were any age groups that would potentially benefit most from immunisation with PPV23; </p><p class=""ql-indent-1"">1.2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Whether repeat dosing would be required for an older patient population due to immunosenescence;</p><p class=""ql-indent-1"">1.2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The relevance of herd immunity to pneumococcal infection; </p><p class=""ql-indent-1"">1.2.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The relevance of the current special groups listed in the Special Authority, and whether these should be revisited.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted an application from Merck, Sharpe and Dohme for pneumococcal 23 valent vaccine (PPV23) to be funded for all persons 65 to 80 years of age who have not received the PPV23 vaccination within the last 5 years and who were not older than 65 years of age at the time of prior vaccination. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that PPV23 is currently funded for children under 5 years of age, and all adults with: HIV infection, for patients post haematopoietic stem cell transplant or chemotherapy, pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency. The Committee noted that PHARMAC also funds one dose of pneumococcal conjugate vaccine (PCV13) for people with chronic conditions who are at higher risk of pneumococcal infection, with a maximum of three doses of PPV23 in a lifetime for revaccination of patients. The Committee noted that approximately 5,000 doses of PPV23 are administered in a year. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that it had previously reviewed applications for PPV23 in the requested population group (once in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">February 2014</a> and again in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">August 2015</a>) and that both applications were recommended for decline. The Committee also noted that the proposal was reviewed by the Immunisation Subcommittee in <a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">February 2015</a>, with no formal recommendation. The Committee noted that at the 2014 meeting, PTAC considered that the evidence of efficacy of PPV23 at a population level was poor, that the evidence for PPV23 in the elderly population was also poor, and that overall incidence of pneumococcal disease was falling. The Committee noted that in 2015, PTAC considered that there was high quality randomised controlled trial evidence of good effect against invasive pneumococcal disease (IPD) however, the strength of the randomised controlled trial evidence against either pneumococcal pneumonia or all-cause pneumonias in the general 65 years of age and over population was weak. PTAC considered that the supplier’s cost-effectiveness model was not robust and could not be tested. The Committee noted that this subsequent resubmission contained new evidence and an updated cost-effectiveness model not previously considered by PTAC or the Immunisation Subcommittee. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that pneumococcal infection can lead to non-bacteraemic pneumococcal pneumonia (NBPP), which is responsible for up to 20% of community acquired pneumonia. The Committee noted that invasive pneumococcal disease (IPD) can present as meningitis or bacteraemia, and that 1 in 4 cases of IPD will suffer from bacteraemia. The Committee noted that IPD is a notifiable disease, and cases must be reported to the Institute of Environmental Science and Research (ESR), so data on incidence in New Zealand is robust. The Committee noted, however, that NBPP is not notifiable and accurate NZ data on incidence and prevalence is not available. The Committee also noted that the health needs of a person with pneumococcal infection are often greater in those with IPD and in those with comorbidities. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that rates of IPD for Māori and Pacific populations in New Zealand is 3.8 and 4.3 times higher than the rate for NZ Europeans, respectively. The Committee noted that of all IPD related mortalities in the Pacific population, 50% occur before the age of 50 years, and for Māori 50% of IPD mortalities occur by 54 years of age. The Committee noted that the IPD mortality rates for NZ Europeans is 50% by 65 years of age. The Committee also noted that Māori comprise approximately 16% of the population but contribute to 50% of total deaths from IPD by 64 years of age. The Committee considered that this demonstrates that the burden of disease from IPD is higher in a population younger than 65 years, and specifically in Māori and Pacific populations. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that in New Zealand the incidence of pneumococcal infection in those over 65 years of age has increased by 21% between 2016 and 2018, however, the incidence has increased 15% in the same time period for those 5-64 years of age. The Committee considered that more information should be sought from the Immunisation Subcommittee regarding any potential benefits if PPV23 were to be funded for a younger population, as well as its view on the age groups that would be the most appropriate to immunise with PPV23. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that PPVs stimulate a T-cell independent immune response, in contrast to PCVs, which stimulate T-cell memory response. The Committee noted that, theoretically, this means that PCV works better in children while PPV works better in adults, due to immunosenescence-related decrease in immune cell memory. The Committee noted that there are over 90 identified pneumococcal serotypes, and that PPV23 covers approximately 72% of the serotypes which are thought to cause disease in those over the age of 65 years in New Zealand, according to IPD data. The Committee noted there are also 15-valent and 20-valent PCVs in development. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted 10 studies relating to the efficacy of PPV23 that have been published since previous PTAC and Subcommittee appraisals: </p><p class=""ql-indent-1"">1.8.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31005428/"" target=""_blank"">Kim et al. Vaccine. 2019;37:2797-804</a>: a hospital based case-control study on the direct effectiveness of pneumococcal polysaccharide vaccine in elderly population. The Committee noted that the adjusted effectiveness against IPD and NBPP was not statistically significant, but when subgroup analysis was performed on the 65-74 age group, the adjusted PPV23 effectiveness was 57.4% against IPD (95% CI 19.4 to 77.5; p=0.009) and 35.0% for NBPP (95% CI 2.3 to 56.7; p=0.038). </p><p class=""ql-indent-1"">1.8.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28126327/"" target=""_blank"">Suzuki et al. Lancet Infect Dis. 2017;17:313-21</a>: a prospective case-control study on the serotype-specific effectiveness of PPV23 against pneumococcal pneumonia in adults aged 65 years or older with community acquired pneumonia. The Committee noted that vaccine effectiveness for NBPP was 20.4% (95% CI 3.4% to 45.6%), and for PPV23 specific serotypes was 33.5% (95% CI 5.6% to 53.1%). </p><p class=""ql-indent-1"">1.8.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28061505/"" target=""_blank"">Falkenhorst et al. PLoS One. 2017;12:e0169368</a>: a systematic review of vaccine efficacy in those aged 65 years and over (three randomised controlled trials, one pseudo-randomised trial, and 13 non-experimental observational trials were included in the analysis). The Committee noted that vaccine efficacy against NBPP was 64% in the randomised controlled trials identified as having low bias, however, the Committee also noted that these trials were heavily weighted by a 2010 Japanese study (<a href=""https://pubmed.ncbi.nlm.nih.gov/20211953/"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a>), with participants recruited from Japanese nursing homes. Additionally, the Committee noted that the meta-analysis reported for the two RCTs selected because of a lower risk of bias, had used the wrong denominators (patient-years rather than number of patients) in their calculations. This study was reviewed by the Immunisation Subcommittee in 2015, at which time the Subcommittee concluded that although the study reported that all causes of pneumonia and pneumococcal pneumonia were significantly higher in the placebo group than in the vaccine group, and that the death rate from pneumococcal pneumonia was also significantly higher in the placebo group than the vaccinated group, the study population may not be comparable to the general New Zealand population aged 65 to 80 years of age.</p><p class=""ql-indent-1"">1.8.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.fhi.no/en/publ/2019/efficacy-and-effectiveness-of-pneumococcal-vaccination-in-adults---an-updat/#:~:text=We%20found%20both%20PPV23%20and,limited%20impact%20of%20waning%20immunity."" target=""_blank"">Winje et al. Norwegian Institute of Public Health. 2019</a>: a review of the efficacy and effectiveness of pneumococcal vaccination (PPV23 and PCV13) in older adults conducted by Norwegian, Swedish and Danish Public Health Institutes. The Committee noted that the randomised controlled trials included in the analysis resulted in a pooled vaccine effectiveness of 76% (95% CI -18% to 95%; I-squared=0%), which is not statistically significant evidence of effectiveness. The pooled vaccine effectiveness from the included cohort studies for the prevention of IPD was 62% (95% CI 37% to 76%; I-squared=24%), including some studies with methodological limitations. </p><p class=""ql-indent-1"">1.8.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32260132/"" target=""_blank"">Berild et al. Pathogens. 2020;9:259</a>: a systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination (PPV 12 and PPV23) on pneumonia and invasive pneumococcal disease in an elderly population. The Committee noted that vaccine efficacy ranging from 3% to 16% against all cause pneumonia, and 50% for IPD (95% CI 15% to 74%) was reported. </p><p class=""ql-indent-1"">1.8.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28542347/"" target=""_blank"">Htar et al. PLoS One. 2017;12:e0177985</a>: a systematic review and meta-analyses of non-experimental observational studies assessing pneumococcal vaccine effectiveness against community-acquired pneumonia in adults among the general population, the immunocompromised and subjects with underlying risk factors in real-world settings. The Committee noted that 33 studies were included, and all participants were over 18 years of age. The Committee noted that vaccine effectiveness in those with community acquired pneumonia over 64 years of age ranged widely from -143% to 60%. The Committee also noted that the meta-analysis estimating vaccine efficacy for any community acquired pneumonia requiring hospitalisation in the general population gave a figure of 10.2% (95% CI -12.6 to 33.0), and that vaccine efficacy for NBPP ranged from 39% to 42% in adults aged 50 years or older in the general population. </p><p class=""ql-indent-1"">1.8.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24484116/"" target=""_blank"">Menzies et al. Med J Aust. 2014;200:112-5</a>: an ecological analysis of trends in IPD notification rates and vaccine effectiveness using data on Australians aged ≥ 65 years (23vPPV funded) and 50-64 years (23vPPV not funded). The Committee noted that the incidence rate ratio for total IPD was 0.65 (95% CI 0.59 to 0.71) for people aged ≥ 65 years, and 0.80 (95% CI 0.71 to 0.90) for people aged 50-64 years. The estimate of 23vPPV effectiveness was 61.1% (95% CI 55.1% to 66.9%).</p><p class=""ql-indent-1"">1.8.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26277073/"" target=""_blank"">Ahn et al. Vaccine. 2015; 33:4770-4775</a>: an evaluation of immune response in 62 participants over the age of 65 (Group 1 aged 65 to 74 years, and Group 2 aged 75 or over), measuring serotype-specific anti-pneumococcal antibodies with opsonophagocytic assay. Geometric mean titres to all tested serotypes signiﬁcantly increased in both groups after vaccination compared to those before vaccination (P&lt;0.001 for all). The Committee noted that study only evaluates immune response rather than more relevant outcomes. </p><p class=""ql-indent-1"">1.8.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27846277/"" target=""_blank"">Baldo et al. PLoS One. 2016;11:e0166637</a>: a retrospective analysis on the mortality rates after a first hospitalisation for community acquired pneumonia in those 65 years of age or over, especially focusing on the role of pneumococcal vaccination as a risk factor associated with pneumonia-related mortality at one year. The Committee noted that of the 4030 people hospitalised with community acquired pneumonia, 3241 had not been vaccinated, 583 had PPV23, and 206 had PCV 13. The Committee noted that death specifically due to pneumonia had a rate of 10.7% (95% CI 6.5% to 14.9%), which was lower than in the unvaccinated or PPV23 groups, with 16.4% (95% CI 15.1% to 17.7%) and 14.1% (95% CI 11.2% to 16.9%), respectively. The Committee also noted that survival rates 1 year after hospitalisation were greatest in the PCV13 group, with survival rates at 1-year after hospitalisation of 83.6%, 85.9% and 89.3% in the unvaccinated, PPV23 and PCV13 groups, respectively. However, the Committee noted that the PCV13 group was very small and that no microbial data was collected so it clear whether the pneumonia cases were caused by pneumococcal or other bacteria. </p><p class=""ql-indent-1"">1.8.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26761816/"" target=""_blank"">Schiffner-Rohe et al. PLoS One. 2016;11:e0146338</a>: a meta-analysis of randomised controlled trials to investigate the effect of PPV23 for preventing community acquired pneumonia in adults 60 years of age or older. The Committee noted that overall, the study concluded that there is no evidence that PPV23 can prevent NBPP in a general, community dwelling population. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the evidence for PPV23 against pneumococcal infection in those aged over 65 to be of poor quality and mixed strength, with low-moderate, inconclusive evidence of efficacy against PPV23 serotypes and IPD, and low-quality evidence and imprecise results for the efficacy of PPV23 against NBPP. The Committee noted that effectiveness was not demonstrated to be consistent in the general population, and that the meta-analyses reported a wide range of effectiveness estimates.\xa0</p><p>1.10.<span style=""font-size: 7pt;""> </span>The Committee noted that its past advice was that PPV23 is effective against IPD, and that more robust evidence is needed to show efficacy against NBPP. The Committee considered that the evidence presented for PPV23 against NBPP is imprecise and of low quality. The Committee noted that although there appears to be limited benefit with PPV23, there would be no additional clinical risk to widening access, and no non-clinical features of the vaccine that would impact on its use by healthcare workers that are different to other vaccines.\xa0</p><p>1.11.<span style=""font-size: 7pt;""> </span>The Committee considered that it is reasonable to assume that uptake of the PPV23 in people aged 65 years of age and older would unlikely be higher than influenza vaccine, however, due to COVID-19 the uptake of influenza vaccine increased in 2020. The Committee also noted that the PPV23 vaccine can be administered at the same time as influenza vaccine, and that uptake may be affected if patients receive both at the same visit. </p><p>1.12.<span style=""font-size: 7pt;""> </span>The Committee noted that data for IPD incidence and mortality show higher rates in those younger than 65 years of age, and in Māori and Pacific populations. The Committee also noted that community acquired pneumonia is more common in those over 70 years of age, and not younger than 65 years. Noting the IPD incidence data for the New Zealand population, the Committee considered that the patient population that might benefit the most from receiving PPV23 are Māori and Pacific people younger than 65 years of age, who have chronic underlying health conditions. The Committee requested the Immunisation Subcommittee’s view on the patient population that would benefit most from this vaccine. </p><p>1.13.<span style=""font-size: 7pt;""> </span>The Committee noted that the response to immunisations in older adults wanes over time due to immunosenescence. Therefore, the Committee considered that there may be a need for repeat dosing requested the Immunisation Subcommittee’s advice on this, especially considering that the most at-risk age group for community acquired pneumonia is those over 70 years of age. </p><p>1.14.<span style=""font-size: 7pt;""> </span>The Committee noted that the correct comparator for the New Zealand context is standard care without funded immunisation (similar to the placebo arms of controlled trials), but that this may change over time if the availability of current PCV vaccine (PCV13) and new pneumococcal conjugate vaccines undergoing clinical trials (PCV15, PCV20) changes.\xa0The Committee noted that if the PPV23 vaccine was effective in preventing IPD and NBPP, then reduced hospital admissions would lead to overall savings for the health sector, however due to the lack of reporting of NBPP hospital admissions, the actual impact and cost to the health sector is currently unknown. </p><p>1.15.<span style=""font-size: 7pt;""> </span>The Committee noted that the supplier has assumed in its application that that NBPP serotype rates match those of IPD. The Committee considered that it had not seen evidence to support this, and that the disease depends not only on serotypes but on the pathogen-host interaction (<a href=""https://pubmed.ncbi.nlm.nih.gov/23341706/"" target=""_blank"">Song et al. J Korean Med Sci. 2013;28:4-15</a>). </p><p>1.16.<span style=""font-size: 7pt;""> </span>The Committee considered that future economic modelling for PPV23 would need to be based on IPD incidence across population and age groups, due to the lack of robust NBPP data. The Committee also considered that any economic modelling should be undertaken following receipt of additional advice from the Immunisation Subcommittee about the most appropriate population groups.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted an application from Merck, Sharpe and Dohme for pneumococcal 23 valent vaccine (PPV23) to be funded for all persons 65 to 80 years of age who have not received the PPV23 vaccination within the last 5 years and who were not older than 65 years of age at the time of prior vaccination. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that PPV23 is currently funded for children under 5 years of age, and all adults with: HIV infection, for patients post haematopoietic stem cell transplant or chemotherapy, pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency. The Committee noted that PHARMAC also funds one dose of pneumococcal conjugate vaccine (PCV13) for people with chronic conditions who are at higher risk of pneumococcal infection, with a maximum of three doses of PPV23 in a lifetime for revaccination of patients. The Committee noted that approximately 5,000 doses of PPV23 are administered in a year. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that it had previously reviewed applications for PPV23 in the requested population group (once in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">February 2014</a> and again in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">August 2015</a>) and that both applications were recommended for decline. The Committee also noted that the proposal was reviewed by the Immunisation Subcommittee in <a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">February 2015</a>, with no formal recommendation. The Committee noted that at the 2014 meeting, PTAC considered that the evidence of efficacy of PPV23 at a population level was poor, that the evidence for PPV23 in the elderly population was also poor, and that overall incidence of pneumococcal disease was falling. The Committee noted that in 2015, PTAC considered that there was high quality randomised controlled trial evidence of good effect against invasive pneumococcal disease (IPD) however, the strength of the randomised controlled trial evidence against either pneumococcal pneumonia or all-cause pneumonias in the general 65 years of age and over population was weak. PTAC considered that the supplier’s cost-effectiveness model was not robust and could not be tested. The Committee noted that this subsequent resubmission contained new evidence and an updated cost-effectiveness model not previously considered by PTAC or the Immunisation Subcommittee. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that pneumococcal infection can lead to non-bacteraemic pneumococcal pneumonia (NBPP), which is responsible for up to 20% of community acquired pneumonia. The Committee noted that invasive pneumococcal disease (IPD) can present as meningitis or bacteraemia, and that 1 in 4 cases of IPD will suffer from bacteraemia. The Committee noted that IPD is a notifiable disease, and cases must be reported to the Institute of Environmental Science and Research (ESR), so data on incidence in New Zealand is robust. The Committee noted, however, that NBPP is not notifiable and accurate NZ data on incidence and prevalence is not available. The Committee also noted that the health needs of a person with pneumococcal infection are often greater in those with IPD and in those with comorbidities. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that rates of IPD for Māori and Pacific populations in New Zealand is 3.8 and 4.3 times higher than the rate for NZ Europeans, respectively. The Committee noted that of all IPD related mortalities in the Pacific population, 50% occur before the age of 50 years, and for Māori 50% of IPD mortalities occur by 54 years of age. The Committee noted that the IPD mortality rates for NZ Europeans is 50% by 65 years of age. The Committee also noted that Māori comprise approximately 16% of the population but contribute to 50% of total deaths from IPD by 64 years of age. The Committee considered that this demonstrates that the burden of disease from IPD is higher in a population younger than 65 years, and specifically in Māori and Pacific populations. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that in New Zealand the incidence of pneumococcal infection in those over 65 years of age has increased by 21% between 2016 and 2018, however, the incidence has increased 15% in the same time period for those 5-64 years of age. The Committee considered that more information should be sought from the Immunisation Subcommittee regarding any potential benefits if PPV23 were to be funded for a younger population, as well as its view on the age groups that would be the most appropriate to immunise with PPV23. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that PPVs stimulate a T-cell independent immune response, in contrast to PCVs, which stimulate T-cell memory response. The Committee noted that, theoretically, this means that PCV works better in children while PPV works better in adults, due to immunosenescence-related decrease in immune cell memory. The Committee noted that there are over 90 identified pneumococcal serotypes, and that PPV23 covers approximately 72% of the serotypes which are thought to cause disease in those over the age of 65 years in New Zealand, according to IPD data. The Committee noted there are also 15-valent and 20-valent PCVs in development. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted 10 studies relating to the efficacy of PPV23 that have been published since previous PTAC and Subcommittee appraisals: </p><p class=""ql-indent-1"">1.8.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31005428/"" target=""_blank"">Kim et al. Vaccine. 2019;37:2797-804</a>: a hospital based case-control study on the direct effectiveness of pneumococcal polysaccharide vaccine in elderly population. The Committee noted that the adjusted effectiveness against IPD and NBPP was not statistically significant, but when subgroup analysis was performed on the 65-74 age group, the adjusted PPV23 effectiveness was 57.4% against IPD (95% CI 19.4 to 77.5; p=0.009) and 35.0% for NBPP (95% CI 2.3 to 56.7; p=0.038). </p><p class=""ql-indent-1"">1.8.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28126327/"" target=""_blank"">Suzuki et al. Lancet Infect Dis. 2017;17:313-21</a>: a prospective case-control study on the serotype-specific effectiveness of PPV23 against pneumococcal pneumonia in adults aged 65 years or older with community acquired pneumonia. The Committee noted that vaccine effectiveness for NBPP was 20.4% (95% CI 3.4% to 45.6%), and for PPV23 specific serotypes was 33.5% (95% CI 5.6% to 53.1%). </p><p class=""ql-indent-1"">1.8.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28061505/"" target=""_blank"">Falkenhorst et al. PLoS One. 2017;12:e0169368</a>: a systematic review of vaccine efficacy in those aged 65 years and over (three randomised controlled trials, one pseudo-randomised trial, and 13 non-experimental observational trials were included in the analysis). The Committee noted that vaccine efficacy against NBPP was 64% in the randomised controlled trials identified as having low bias, however, the Committee also noted that these trials were heavily weighted by a 2010 Japanese study (<a href=""https://pubmed.ncbi.nlm.nih.gov/20211953/"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a>), with participants recruited from Japanese nursing homes. Additionally, the Committee noted that the meta-analysis reported for the two RCTs selected because of a lower risk of bias, had used the wrong denominators (patient-years rather than number of patients) in their calculations. This study was reviewed by the Immunisation Subcommittee in 2015, at which time the Subcommittee concluded that although the study reported that all causes of pneumonia and pneumococcal pneumonia were significantly higher in the placebo group than in the vaccine group, and that the death rate from pneumococcal pneumonia was also significantly higher in the placebo group than the vaccinated group, the study population may not be comparable to the general New Zealand population aged 65 to 80 years of age.</p><p class=""ql-indent-1"">1.8.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.fhi.no/en/publ/2019/efficacy-and-effectiveness-of-pneumococcal-vaccination-in-adults---an-updat/#:~:text=We%20found%20both%20PPV23%20and,limited%20impact%20of%20waning%20immunity."" target=""_blank"">Winje et al. Norwegian Institute of Public Health. 2019</a>: a review of the efficacy and effectiveness of pneumococcal vaccination (PPV23 and PCV13) in older adults conducted by Norwegian, Swedish and Danish Public Health Institutes. The Committee noted that the randomised controlled trials included in the analysis resulted in a pooled vaccine effectiveness of 76% (95% CI -18% to 95%; I-squared=0%), which is not statistically significant evidence of effectiveness. The pooled vaccine effectiveness from the included cohort studies for the prevention of IPD was 62% (95% CI 37% to 76%; I-squared=24%), including some studies with methodological limitations. </p><p class=""ql-indent-1"">1.8.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32260132/"" target=""_blank"">Berild et al. Pathogens. 2020;9:259</a>: a systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination (PPV 12 and PPV23) on pneumonia and invasive pneumococcal disease in an elderly population. The Committee noted that vaccine efficacy ranging from 3% to 16% against all cause pneumonia, and 50% for IPD (95% CI 15% to 74%) was reported. </p><p class=""ql-indent-1"">1.8.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28542347/"" target=""_blank"">Htar et al. PLoS One. 2017;12:e0177985</a>: a systematic review and meta-analyses of non-experimental observational studies assessing pneumococcal vaccine effectiveness against community-acquired pneumonia in adults among the general population, the immunocompromised and subjects with underlying risk factors in real-world settings. The Committee noted that 33 studies were included, and all participants were over 18 years of age. The Committee noted that vaccine effectiveness in those with community acquired pneumonia over 64 years of age ranged widely from -143% to 60%. The Committee also noted that the meta-analysis estimating vaccine efficacy for any community acquired pneumonia requiring hospitalisation in the general population gave a figure of 10.2% (95% CI -12.6 to 33.0), and that vaccine efficacy for NBPP ranged from 39% to 42% in adults aged 50 years or older in the general population. </p><p class=""ql-indent-1"">1.8.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24484116/"" target=""_blank"">Menzies et al. Med J Aust. 2014;200:112-5</a>: an ecological analysis of trends in IPD notification rates and vaccine effectiveness using data on Australians aged ≥ 65 years (23vPPV funded) and 50-64 years (23vPPV not funded). The Committee noted that the incidence rate ratio for total IPD was 0.65 (95% CI 0.59 to 0.71) for people aged ≥ 65 years, and 0.80 (95% CI 0.71 to 0.90) for people aged 50-64 years. The estimate of 23vPPV effectiveness was 61.1% (95% CI 55.1% to 66.9%).</p><p class=""ql-indent-1"">1.8.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26277073/"" target=""_blank"">Ahn et al. Vaccine. 2015; 33:4770-4775</a>: an evaluation of immune response in 62 participants over the age of 65 (Group 1 aged 65 to 74 years, and Group 2 aged 75 or over), measuring serotype-specific anti-pneumococcal antibodies with opsonophagocytic assay. Geometric mean titres to all tested serotypes signiﬁcantly increased in both groups after vaccination compared to those before vaccination (P&lt;0.001 for all). The Committee noted that study only evaluates immune response rather than more relevant outcomes. </p><p class=""ql-indent-1"">1.8.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27846277/"" target=""_blank"">Baldo et al. PLoS One. 2016;11:e0166637</a>: a retrospective analysis on the mortality rates after a first hospitalisation for community acquired pneumonia in those 65 years of age or over, especially focusing on the role of pneumococcal vaccination as a risk factor associated with pneumonia-related mortality at one year. The Committee noted that of the 4030 people hospitalised with community acquired pneumonia, 3241 had not been vaccinated, 583 had PPV23, and 206 had PCV 13. The Committee noted that death specifically due to pneumonia had a rate of 10.7% (95% CI 6.5% to 14.9%), which was lower than in the unvaccinated or PPV23 groups, with 16.4% (95% CI 15.1% to 17.7%) and 14.1% (95% CI 11.2% to 16.9%), respectively. The Committee also noted that survival rates 1 year after hospitalisation were greatest in the PCV13 group, with survival rates at 1-year after hospitalisation of 83.6%, 85.9% and 89.3% in the unvaccinated, PPV23 and PCV13 groups, respectively. However, the Committee noted that the PCV13 group was very small and that no microbial data was collected so it clear whether the pneumonia cases were caused by pneumococcal or other bacteria. </p><p class=""ql-indent-1"">1.8.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26761816/"" target=""_blank"">Schiffner-Rohe et al. PLoS One. 2016;11:e0146338</a>: a meta-analysis of randomised controlled trials to investigate the effect of PPV23 for preventing community acquired pneumonia in adults 60 years of age or older. The Committee noted that overall, the study concluded that there is no evidence that PPV23 can prevent NBPP in a general, community dwelling population. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the evidence for PPV23 against pneumococcal infection in those aged over 65 to be of poor quality and mixed strength, with low-moderate, inconclusive evidence of efficacy against PPV23 serotypes and IPD, and low-quality evidence and imprecise results for the efficacy of PPV23 against NBPP. The Committee noted that effectiveness was not demonstrated to be consistent in the general population, and that the meta-analyses reported a wide range of effectiveness estimates.\xa0</p><p>1.10.<span style=""font-size: 7pt;""> </span>The Committee noted that its past advice was that PPV23 is effective against IPD, and that more robust evidence is needed to show efficacy against NBPP. The Committee considered that the evidence presented for PPV23 against NBPP is imprecise and of low quality. The Committee noted that although there appears to be limited benefit with PPV23, there would be no additional clinical risk to widening access, and no non-clinical features of the vaccine that would impact on its use by healthcare workers that are different to other vaccines.\xa0</p><p>1.11.<span style=""font-size: 7pt;""> </span>The Committee considered that it is reasonable to assume that uptake of the PPV23 in people aged 65 years of age and older would unlikely be higher than influenza vaccine, however, due to COVID-19 the uptake of influenza vaccine increased in 2020. The Committee also noted that the PPV23 vaccine can be administered at the same time as influenza vaccine, and that uptake may be affected if patients receive both at the same visit. </p><p>1.12.<span style=""font-size: 7pt;""> </span>The Committee noted that data for IPD incidence and mortality show higher rates in those younger than 65 years of age, and in Māori and Pacific populations. The Committee also noted that community acquired pneumonia is more common in those over 70 years of age, and not younger than 65 years. Noting the IPD incidence data for the New Zealand population, the Committee considered that the patient population that might benefit the most from receiving PPV23 are Māori and Pacific people younger than 65 years of age, who have chronic underlying health conditions. The Committee requested the Immunisation Subcommittee’s view on the patient population that would benefit most from this vaccine. </p><p>1.13.<span style=""font-size: 7pt;""> </span>The Committee noted that the response to immunisations in older adults wanes over time due to immunosenescence. Therefore, the Committee considered that there may be a need for repeat dosing requested the Immunisation Subcommittee’s advice on this, especially considering that the most at-risk age group for community acquired pneumonia is those over 70 years of age. </p><p>1.14.<span style=""font-size: 7pt;""> </span>The Committee noted that the correct comparator for the New Zealand context is standard care without funded immunisation (similar to the placebo arms of controlled trials), but that this may change over time if the availability of current PCV vaccine (PCV13) and new pneumococcal conjugate vaccines undergoing clinical trials (PCV15, PCV20) changes.\xa0The Committee noted that if the PPV23 vaccine was effective in preventing IPD and NBPP, then reduced hospital admissions would lead to overall savings for the health sector, however due to the lack of reporting of NBPP hospital admissions, the actual impact and cost to the health sector is currently unknown. </p><p>1.15.<span style=""font-size: 7pt;""> </span>The Committee noted that the supplier has assumed in its application that that NBPP serotype rates match those of IPD. The Committee considered that it had not seen evidence to support this, and that the disease depends not only on serotypes but on the pathogen-host interaction (<a href=""https://pubmed.ncbi.nlm.nih.gov/23341706/"" target=""_blank"">Song et al. J Korean Med Sci. 2013;28:4-15</a>). </p><p>1.16.<span style=""font-size: 7pt;""> </span>The Committee considered that future economic modelling for PPV23 would need to be based on IPD incidence across population and age groups, due to the lack of robust NBPP data. The Committee also considered that any economic modelling should be undertaken following receipt of additional advice from the Immunisation Subcommittee about the most appropriate population groups.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee reviewed a supplier application for 23 valent pneumococcal polysaccharide vaccine for the immunisation of people 65 years of age and over. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee reviewed a supplier application for 23 valent pneumococcal polysaccharide vaccine for the immunisation of people 65 years of age and over. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 25 March 2021.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 25 March 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heyge2AB'}, 'Id': 'a0POZ00000Heyge2AB', 'Event_Date__c': '2021-06-15', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 25 March 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Jun 2021', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee <b>recommended</b> that p<span style=""color: black;"">neumococcal polysaccharide vaccine (PPV23) </span>for the <span style=""color: black;"">immunisation of all people 65 years of age and over</span> be <b>declined</b>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered that further advice is required from the Immunisation Subcommittee regarding: </p><p class=""ql-indent-1"">1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The possible risks and benefits of funding the PPV23 for Māori; and additionally for Pacific people and others facing health disparities as a result of underlying disadvantage who are also under 65 years of age, and finally for those with comorbidities such as COPD or rheumatic heart disease; </p><p class=""ql-indent-1"">1.2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The possible risks and benefits of funding the PPV23 for the general population under 65 years of age and whether there were any age groups that would potentially benefit most from immunisation with PPV23; </p><p class=""ql-indent-1"">1.2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>Whether repeat dosing would be required for an older patient population due to immunosenescence;</p><p class=""ql-indent-1"">1.2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The relevance of herd immunity to pneumococcal infection; </p><p class=""ql-indent-1"">1.2.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The relevance of the current special groups listed in the Special Authority, and whether these should be revisited.</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee reviewed a supplier application for 23 valent pneumococcal polysaccharide vaccine for the immunisation of people 65 years of age and over. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted an application from Merck, Sharpe and Dohme for pneumococcal 23 valent vaccine (PPV23) to be funded for all persons 65 to 80 years of age who have not received the PPV23 vaccination within the last 5 years and who were not older than 65 years of age at the time of prior vaccination. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that PPV23 is currently funded for children under 5 years of age, and all adults with: HIV infection, for patients post haematopoietic stem cell transplant or chemotherapy, pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency. The Committee noted that PHARMAC also funds one dose of pneumococcal conjugate vaccine (PCV13) for people with chronic conditions who are at higher risk of pneumococcal infection, with a maximum of three doses of PPV23 in a lifetime for revaccination of patients. The Committee noted that approximately 5,000 doses of PPV23 are administered in a year. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that it had previously reviewed applications for PPV23 in the requested population group (once in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">February 2014</a> and again in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">August 2015</a>) and that both applications were recommended for decline. The Committee also noted that the proposal was reviewed by the Immunisation Subcommittee in <a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">February 2015</a>, with no formal recommendation. The Committee noted that at the 2014 meeting, PTAC considered that the evidence of efficacy of PPV23 at a population level was poor, that the evidence for PPV23 in the elderly population was also poor, and that overall incidence of pneumococcal disease was falling. The Committee noted that in 2015, PTAC considered that there was high quality randomised controlled trial evidence of good effect against invasive pneumococcal disease (IPD) however, the strength of the randomised controlled trial evidence against either pneumococcal pneumonia or all-cause pneumonias in the general 65 years of age and over population was weak. PTAC considered that the supplier’s cost-effectiveness model was not robust and could not be tested. The Committee noted that this subsequent resubmission contained new evidence and an updated cost-effectiveness model not previously considered by PTAC or the Immunisation Subcommittee. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that pneumococcal infection can lead to non-bacteraemic pneumococcal pneumonia (NBPP), which is responsible for up to 20% of community acquired pneumonia. The Committee noted that invasive pneumococcal disease (IPD) can present as meningitis or bacteraemia, and that 1 in 4 cases of IPD will suffer from bacteraemia. The Committee noted that IPD is a notifiable disease, and cases must be reported to the Institute of Environmental Science and Research (ESR), so data on incidence in New Zealand is robust. The Committee noted, however, that NBPP is not notifiable and accurate NZ data on incidence and prevalence is not available. The Committee also noted that the health needs of a person with pneumococcal infection are often greater in those with IPD and in those with comorbidities. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that rates of IPD for Māori and Pacific populations in New Zealand is 3.8 and 4.3 times higher than the rate for NZ Europeans, respectively. The Committee noted that of all IPD related mortalities in the Pacific population, 50% occur before the age of 50 years, and for Māori 50% of IPD mortalities occur by 54 years of age. The Committee noted that the IPD mortality rates for NZ Europeans is 50% by 65 years of age. The Committee also noted that Māori comprise approximately 16% of the population but contribute to 50% of total deaths from IPD by 64 years of age. The Committee considered that this demonstrates that the burden of disease from IPD is higher in a population younger than 65 years, and specifically in Māori and Pacific populations. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that in New Zealand the incidence of pneumococcal infection in those over 65 years of age has increased by 21% between 2016 and 2018, however, the incidence has increased 15% in the same time period for those 5-64 years of age. The Committee considered that more information should be sought from the Immunisation Subcommittee regarding any potential benefits if PPV23 were to be funded for a younger population, as well as its view on the age groups that would be the most appropriate to immunise with PPV23. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that PPVs stimulate a T-cell independent immune response, in contrast to PCVs, which stimulate T-cell memory response. The Committee noted that, theoretically, this means that PCV works better in children while PPV works better in adults, due to immunosenescence-related decrease in immune cell memory. The Committee noted that there are over 90 identified pneumococcal serotypes, and that PPV23 covers approximately 72% of the serotypes which are thought to cause disease in those over the age of 65 years in New Zealand, according to IPD data. The Committee noted there are also 15-valent and 20-valent PCVs in development. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted 10 studies relating to the efficacy of PPV23 that have been published since previous PTAC and Subcommittee appraisals: </p><p class=""ql-indent-1"">1.8.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31005428/"" target=""_blank"">Kim et al. Vaccine. 2019;37:2797-804</a>: a hospital based case-control study on the direct effectiveness of pneumococcal polysaccharide vaccine in elderly population. The Committee noted that the adjusted effectiveness against IPD and NBPP was not statistically significant, but when subgroup analysis was performed on the 65-74 age group, the adjusted PPV23 effectiveness was 57.4% against IPD (95% CI 19.4 to 77.5; p=0.009) and 35.0% for NBPP (95% CI 2.3 to 56.7; p=0.038). </p><p class=""ql-indent-1"">1.8.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28126327/"" target=""_blank"">Suzuki et al. Lancet Infect Dis. 2017;17:313-21</a>: a prospective case-control study on the serotype-specific effectiveness of PPV23 against pneumococcal pneumonia in adults aged 65 years or older with community acquired pneumonia. The Committee noted that vaccine effectiveness for NBPP was 20.4% (95% CI 3.4% to 45.6%), and for PPV23 specific serotypes was 33.5% (95% CI 5.6% to 53.1%). </p><p class=""ql-indent-1"">1.8.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28061505/"" target=""_blank"">Falkenhorst et al. PLoS One. 2017;12:e0169368</a>: a systematic review of vaccine efficacy in those aged 65 years and over (three randomised controlled trials, one pseudo-randomised trial, and 13 non-experimental observational trials were included in the analysis). The Committee noted that vaccine efficacy against NBPP was 64% in the randomised controlled trials identified as having low bias, however, the Committee also noted that these trials were heavily weighted by a 2010 Japanese study (<a href=""https://pubmed.ncbi.nlm.nih.gov/20211953/"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a>), with participants recruited from Japanese nursing homes. Additionally, the Committee noted that the meta-analysis reported for the two RCTs selected because of a lower risk of bias, had used the wrong denominators (patient-years rather than number of patients) in their calculations. This study was reviewed by the Immunisation Subcommittee in 2015, at which time the Subcommittee concluded that although the study reported that all causes of pneumonia and pneumococcal pneumonia were significantly higher in the placebo group than in the vaccine group, and that the death rate from pneumococcal pneumonia was also significantly higher in the placebo group than the vaccinated group, the study population may not be comparable to the general New Zealand population aged 65 to 80 years of age.</p><p class=""ql-indent-1"">1.8.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.fhi.no/en/publ/2019/efficacy-and-effectiveness-of-pneumococcal-vaccination-in-adults---an-updat/#:~:text=We%20found%20both%20PPV23%20and,limited%20impact%20of%20waning%20immunity."" target=""_blank"">Winje et al. Norwegian Institute of Public Health. 2019</a>: a review of the efficacy and effectiveness of pneumococcal vaccination (PPV23 and PCV13) in older adults conducted by Norwegian, Swedish and Danish Public Health Institutes. The Committee noted that the randomised controlled trials included in the analysis resulted in a pooled vaccine effectiveness of 76% (95% CI -18% to 95%; I-squared=0%), which is not statistically significant evidence of effectiveness. The pooled vaccine effectiveness from the included cohort studies for the prevention of IPD was 62% (95% CI 37% to 76%; I-squared=24%), including some studies with methodological limitations. </p><p class=""ql-indent-1"">1.8.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32260132/"" target=""_blank"">Berild et al. Pathogens. 2020;9:259</a>: a systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination (PPV 12 and PPV23) on pneumonia and invasive pneumococcal disease in an elderly population. The Committee noted that vaccine efficacy ranging from 3% to 16% against all cause pneumonia, and 50% for IPD (95% CI 15% to 74%) was reported. </p><p class=""ql-indent-1"">1.8.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28542347/"" target=""_blank"">Htar et al. PLoS One. 2017;12:e0177985</a>: a systematic review and meta-analyses of non-experimental observational studies assessing pneumococcal vaccine effectiveness against community-acquired pneumonia in adults among the general population, the immunocompromised and subjects with underlying risk factors in real-world settings. The Committee noted that 33 studies were included, and all participants were over 18 years of age. The Committee noted that vaccine effectiveness in those with community acquired pneumonia over 64 years of age ranged widely from -143% to 60%. The Committee also noted that the meta-analysis estimating vaccine efficacy for any community acquired pneumonia requiring hospitalisation in the general population gave a figure of 10.2% (95% CI -12.6 to 33.0), and that vaccine efficacy for NBPP ranged from 39% to 42% in adults aged 50 years or older in the general population. </p><p class=""ql-indent-1"">1.8.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24484116/"" target=""_blank"">Menzies et al. Med J Aust. 2014;200:112-5</a>: an ecological analysis of trends in IPD notification rates and vaccine effectiveness using data on Australians aged ≥ 65 years (23vPPV funded) and 50-64 years (23vPPV not funded). The Committee noted that the incidence rate ratio for total IPD was 0.65 (95% CI 0.59 to 0.71) for people aged ≥ 65 years, and 0.80 (95% CI 0.71 to 0.90) for people aged 50-64 years. The estimate of 23vPPV effectiveness was 61.1% (95% CI 55.1% to 66.9%).</p><p class=""ql-indent-1"">1.8.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26277073/"" target=""_blank"">Ahn et al. Vaccine. 2015; 33:4770-4775</a>: an evaluation of immune response in 62 participants over the age of 65 (Group 1 aged 65 to 74 years, and Group 2 aged 75 or over), measuring serotype-specific anti-pneumococcal antibodies with opsonophagocytic assay. Geometric mean titres to all tested serotypes signiﬁcantly increased in both groups after vaccination compared to those before vaccination (P&lt;0.001 for all). The Committee noted that study only evaluates immune response rather than more relevant outcomes. </p><p class=""ql-indent-1"">1.8.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27846277/"" target=""_blank"">Baldo et al. PLoS One. 2016;11:e0166637</a>: a retrospective analysis on the mortality rates after a first hospitalisation for community acquired pneumonia in those 65 years of age or over, especially focusing on the role of pneumococcal vaccination as a risk factor associated with pneumonia-related mortality at one year. The Committee noted that of the 4030 people hospitalised with community acquired pneumonia, 3241 had not been vaccinated, 583 had PPV23, and 206 had PCV 13. The Committee noted that death specifically due to pneumonia had a rate of 10.7% (95% CI 6.5% to 14.9%), which was lower than in the unvaccinated or PPV23 groups, with 16.4% (95% CI 15.1% to 17.7%) and 14.1% (95% CI 11.2% to 16.9%), respectively. The Committee also noted that survival rates 1 year after hospitalisation were greatest in the PCV13 group, with survival rates at 1-year after hospitalisation of 83.6%, 85.9% and 89.3% in the unvaccinated, PPV23 and PCV13 groups, respectively. However, the Committee noted that the PCV13 group was very small and that no microbial data was collected so it clear whether the pneumonia cases were caused by pneumococcal or other bacteria. </p><p class=""ql-indent-1"">1.8.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26761816/"" target=""_blank"">Schiffner-Rohe et al. PLoS One. 2016;11:e0146338</a>: a meta-analysis of randomised controlled trials to investigate the effect of PPV23 for preventing community acquired pneumonia in adults 60 years of age or older. The Committee noted that overall, the study concluded that there is no evidence that PPV23 can prevent NBPP in a general, community dwelling population. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the evidence for PPV23 against pneumococcal infection in those aged over 65 to be of poor quality and mixed strength, with low-moderate, inconclusive evidence of efficacy against PPV23 serotypes and IPD, and low-quality evidence and imprecise results for the efficacy of PPV23 against NBPP. The Committee noted that effectiveness was not demonstrated to be consistent in the general population, and that the meta-analyses reported a wide range of effectiveness estimates.\xa0</p><p>1.10.<span style=""font-size: 7pt;""> </span>The Committee noted that its past advice was that PPV23 is effective against IPD, and that more robust evidence is needed to show efficacy against NBPP. The Committee considered that the evidence presented for PPV23 against NBPP is imprecise and of low quality. The Committee noted that although there appears to be limited benefit with PPV23, there would be no additional clinical risk to widening access, and no non-clinical features of the vaccine that would impact on its use by healthcare workers that are different to other vaccines.\xa0</p><p>1.11.<span style=""font-size: 7pt;""> </span>The Committee considered that it is reasonable to assume that uptake of the PPV23 in people aged 65 years of age and older would unlikely be higher than influenza vaccine, however, due to COVID-19 the uptake of influenza vaccine increased in 2020. The Committee also noted that the PPV23 vaccine can be administered at the same time as influenza vaccine, and that uptake may be affected if patients receive both at the same visit. </p><p>1.12.<span style=""font-size: 7pt;""> </span>The Committee noted that data for IPD incidence and mortality show higher rates in those younger than 65 years of age, and in Māori and Pacific populations. The Committee also noted that community acquired pneumonia is more common in those over 70 years of age, and not younger than 65 years. Noting the IPD incidence data for the New Zealand population, the Committee considered that the patient population that might benefit the most from receiving PPV23 are Māori and Pacific people younger than 65 years of age, who have chronic underlying health conditions. The Committee requested the Immunisation Subcommittee’s view on the patient population that would benefit most from this vaccine. </p><p>1.13.<span style=""font-size: 7pt;""> </span>The Committee noted that the response to immunisations in older adults wanes over time due to immunosenescence. Therefore, the Committee considered that there may be a need for repeat dosing requested the Immunisation Subcommittee’s advice on this, especially considering that the most at-risk age group for community acquired pneumonia is those over 70 years of age. </p><p>1.14.<span style=""font-size: 7pt;""> </span>The Committee noted that the correct comparator for the New Zealand context is standard care without funded immunisation (similar to the placebo arms of controlled trials), but that this may change over time if the availability of current PCV vaccine (PCV13) and new pneumococcal conjugate vaccines undergoing clinical trials (PCV15, PCV20) changes.\xa0The Committee noted that if the PPV23 vaccine was effective in preventing IPD and NBPP, then reduced hospital admissions would lead to overall savings for the health sector, however due to the lack of reporting of NBPP hospital admissions, the actual impact and cost to the health sector is currently unknown. </p><p>1.15.<span style=""font-size: 7pt;""> </span>The Committee noted that the supplier has assumed in its application that that NBPP serotype rates match those of IPD. The Committee considered that it had not seen evidence to support this, and that the disease depends not only on serotypes but on the pathogen-host interaction (<a href=""https://pubmed.ncbi.nlm.nih.gov/23341706/"" target=""_blank"">Song et al. J Korean Med Sci. 2013;28:4-15</a>). </p><p>1.16.<span style=""font-size: 7pt;""> </span>The Committee considered that future economic modelling for PPV23 would need to be based on IPD incidence across population and age groups, due to the lack of robust NBPP data. The Committee also considered that any economic modelling should be undertaken following receipt of additional advice from the Immunisation Subcommittee about the most appropriate population groups.\xa0</p>', 'Status_History__c': 'a132P000000DRHJQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2021', 'fs': 'Jul 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Immunisation Subcommittee meeting to provide advice on Tuesday 10 August 2021', 'fs': 'Assigned to Immunisation Subcommittee meeting to provide advice on Tuesday 10 August 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygf2AB'}, 'Id': 'a0POZ00000Heygf2AB', 'Event_Date__c': '2021-07-22', 'Event_Description__c': 'Assigned to Immunisation Subcommittee meeting to provide advice on Tuesday 10 August 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2021', 'Status_History__c': 'a132P000000D22fQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended </b>that the 23 valent pneumococcal polysaccharide vaccine for people over the age of 65 be <b>declined</b>.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered:</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the low-quality evidence and imprecise results for the efficacy of PPV23 against non-bacteraemic pneumococcal pneumonia;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>inconclusive evidence of efficacy against PPV23 serotypes and invasive pneumococcal disease (IPD);</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the lack of evidence for benefit for the Māori and Pacific populations;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the lack of data in people over the age of 60 who had risk factors other than hospitalisation;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>that the addition of conjugate pneumococcal vaccine 13-valent (PCV13) is likely needed prior to receiving PPV23 for patients to receive any measurable benefit.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended </b>that the 23 valent pneumococcal polysaccharide vaccine for people over the age of 65 be <b>declined</b>.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered:</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the low-quality evidence and imprecise results for the efficacy of PPV23 against non-bacteraemic pneumococcal pneumonia;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>inconclusive evidence of efficacy against PPV23 serotypes and invasive pneumococcal disease (IPD);</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the lack of evidence for benefit for the Māori and Pacific populations;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the lack of data in people over the age of 60 who had risk factors other than hospitalisation;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>that the addition of conjugate pneumococcal vaccine 13-valent (PCV13) is likely needed prior to receiving PPV23 for patients to receive any measurable benefit.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PPV23 has been previously considered by both PTAC and the Immunisation Subcommittee on multiple occasions:</p><p class=""ql-indent-1"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">February 2014</a> where an application for people aged 65 years and over was recommended for decline;</p><p class=""ql-indent-1"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By The Immunisation Subcommittee in <a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">February 2015</a> where no formal recommendation was given;</p><p class=""ql-indent-1"">1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">August 2015</a> where an application for people aged 65 years and over was recommended for decline.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application was most recently reviewed by PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2021-03.pdf"" target=""_blank"">March 2021</a>, where it was again recommended for decline. The Subcommittee noted that PTAC considered the evidence for PPV23 against pneumococcal infection in those aged over 65 to be of poor quality and mixed strength, with low-moderate, inconclusive evidence of efficacy against PPV23 serotypes and invasive pneumococcal disease (IPD), and low-quality evidence and imprecise results for the efficacy of PPV23 against non-bacteraemic pneumococcal pneumonia (NBPP). PTAC also noted that effectiveness was not demonstrated to be consistent in the general population, and that the meta-analyses reported a wide range of effectiveness estimates. The Subcommittee noted PTAC’s past advice was that PPV23 is effective against IPD, and that more robust evidence is needed to show efficacy against NBPP. PTAC also considered that the evidence presented for PPV23 against NBPP is imprecise and of low quality. The Subcommittee noted that PTAC considered that although there appears to be limited benefit with PPV23, there would be no additional clinical risk to widening access, and no non-clinical features of the vaccine that would impact on its use by healthcare workers that are different to other vaccines. The Subcommittee noted and agreed with PTAC’s considerations and recommendation.\xa0</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that pneumococcal infection is a common disease that affects all age groups and has the potential to cause significant illness, sometimes leading to hospitalisation or death. The Subcommittee noted that in 2019 the rate of invasive pneumococcal disease was 25 per 100,000 population for those aged 65-80 years, and that Māori and Pacific people are overrepresented, with rates of 37.0 and 28.9 per 100,000, respectively. The Subcommittee noted that <i>S. pneumoniae </i>is the underlying pathogen in 30-50% of cases of NBPP. The Subcommittee noted 16 people aged 65 or over died in 2018 as a result of pneumococcal infection. The Subcommittee noted that any herd immunity effects from the childhood pneumococcal vaccination programme has not reduced the pneumococcal related mortality rates in the over 65-year age group.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PPV23 vaccine is currently funded on the Pharmaceutical Schedule for vaccination of adults aged 18 years and older with HIV infection; who are pre- or post-HSCT or chemotherapy; who are pre- or post-splenectomy or with functional asplenia; who are pre- or post-solid organ transplant; undergoing renal dialysis; with complement deficiency (acquired or inherited); with cochlear implants; with primary immunodeficiency. The Subcommittee noted that Pharmac also funds one dose of pneumococcal conjugate vaccine (PCV13) for people with chronic conditions who are at higher risk of pneumococcal infection with a maximum of three doses of PPV23 in a lifetime for revaccination of patients, and for those between the age of 12 months and 18 years who have previously received two doses of the primary course of PCV10.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PPV23 vaccine includes antigens of 23 different serotypes of <i>S. pneumoniae</i>, which are responsible for more than 90% of cases of invasive pneumococcal (<a href=""https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease"" target=""_blank"">WHO 2003</a>). The Subcommittee noted that the recommended dosage of PPV23 is a single 0.5 mL dose of Pneumovax 23 subcutaneously or intramuscularly.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following evidence relating to the use of PPV23 in the prevention of pneumococcal disease in the 65–80-year age group:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31005428/"" target=""_blank"">Kim et al. Vaccine. 2019;37:2797-804</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28126327/"" target=""_blank"">Suzuki et al. Lancet Infect Dis. 2017;17:313-21</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/16941367/"" target=""_blank"">Vila-Corcoles et al. Clin Infect Dis. 2006;43:860-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20211953/"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24613522/"" target=""_blank"">Wiemken et al. Vaccine. 2014;32(19):2198-203</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24532544/"" target=""_blank"">Ochpa-Gondar et al. Clin Infect Dis. 2014;58:909-17</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23440780/"" target=""_blank"">Moberly et al. Cochrane Database Syst Rev 2013:CD000422</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28061505/"" target=""_blank"">Falkenhorst et al. PLoS One. 2017;12:e0169368</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.fhi.no/en/publ/2019/efficacy-and-effectiveness-of-pneumococcal-vaccination-in-adults---an-updat/#:~:text=We%20found%20both%20PPV23%20and,limited%20impact%20of%20waning%20immunity."" target=""_blank"">Winje et al. Norwegian Institute of Public Health. 2019</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32260132/"" target=""_blank"">Berild et al. Pathogens. 2020;9:259</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24484116/"" target=""_blank"">Menzies et al. Med J Aust. 2014;200:112-5</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26277073/"" target=""_blank"">Ahn et al. Vaccine. 2015; 33:4770-4775</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.bmj.com/content/340/bmj.c1004"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28542347/"" target=""_blank"">Htar et al. PLoS One. 2017;12:e0177985</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27846277/"" target=""_blank"">Baldo et al. PLoS One. 2016;11:e0166637</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26761816/"" target=""_blank"">Schiffner-Rohe et al. PLoS One. 2016;11:e0146338</a></p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that since PPVs stimulate a T-cell independent immune response, in contrast to PCVs, which stimulate T-cell memory response, PCV13 may have to be given in conjunction with PPV23 in order to achieve a benefit in the 65 year and over population.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted and agreed with PTAC’s consideration that there is a lack of evidence of effect for preventing non-bacteraemic pneumococcal pneumonia, a lack of evidence that PPV23 would reduce inequity in the Māori and Pacific population, there is insufficient data regarding the use of PPV23 in people between the ages of 60 and 65, that estimates of beneficial effect were wide and imprecise, and that the addition of conjugate pneumococcal vaccine 13-valent (PCV13) is likely needed prior to receiving PPV23 for patients to receive any measurable benefit.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for pneumococcal 23-valent vaccine if it were to be funded in New Zealand for people aged over 65 years<span style=""font-size: 8pt;"">.</span> This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000Heygg&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001lgs8"" alt=""image.png""></img></p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PPV23 has been previously considered by both PTAC and the Immunisation Subcommittee on multiple occasions:</p><p class=""ql-indent-1"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">February 2014</a> where an application for people aged 65 years and over was recommended for decline;</p><p class=""ql-indent-1"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By The Immunisation Subcommittee in <a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">February 2015</a> where no formal recommendation was given;</p><p class=""ql-indent-1"">1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">August 2015</a> where an application for people aged 65 years and over was recommended for decline.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application was most recently reviewed by PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2021-03.pdf"" target=""_blank"">March 2021</a>, where it was again recommended for decline. The Subcommittee noted that PTAC considered the evidence for PPV23 against pneumococcal infection in those aged over 65 to be of poor quality and mixed strength, with low-moderate, inconclusive evidence of efficacy against PPV23 serotypes and invasive pneumococcal disease (IPD), and low-quality evidence and imprecise results for the efficacy of PPV23 against non-bacteraemic pneumococcal pneumonia (NBPP). PTAC also noted that effectiveness was not demonstrated to be consistent in the general population, and that the meta-analyses reported a wide range of effectiveness estimates. The Subcommittee noted PTAC’s past advice was that PPV23 is effective against IPD, and that more robust evidence is needed to show efficacy against NBPP. PTAC also considered that the evidence presented for PPV23 against NBPP is imprecise and of low quality. The Subcommittee noted that PTAC considered that although there appears to be limited benefit with PPV23, there would be no additional clinical risk to widening access, and no non-clinical features of the vaccine that would impact on its use by healthcare workers that are different to other vaccines. The Subcommittee noted and agreed with PTAC’s considerations and recommendation.\xa0</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that pneumococcal infection is a common disease that affects all age groups and has the potential to cause significant illness, sometimes leading to hospitalisation or death. The Subcommittee noted that in 2019 the rate of invasive pneumococcal disease was 25 per 100,000 population for those aged 65-80 years, and that Māori and Pacific people are overrepresented, with rates of 37.0 and 28.9 per 100,000, respectively. The Subcommittee noted that <i>S. pneumoniae </i>is the underlying pathogen in 30-50% of cases of NBPP. The Subcommittee noted 16 people aged 65 or over died in 2018 as a result of pneumococcal infection. The Subcommittee noted that any herd immunity effects from the childhood pneumococcal vaccination programme has not reduced the pneumococcal related mortality rates in the over 65-year age group.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PPV23 vaccine is currently funded on the Pharmaceutical Schedule for vaccination of adults aged 18 years and older with HIV infection; who are pre- or post-HSCT or chemotherapy; who are pre- or post-splenectomy or with functional asplenia; who are pre- or post-solid organ transplant; undergoing renal dialysis; with complement deficiency (acquired or inherited); with cochlear implants; with primary immunodeficiency. The Subcommittee noted that Pharmac also funds one dose of pneumococcal conjugate vaccine (PCV13) for people with chronic conditions who are at higher risk of pneumococcal infection with a maximum of three doses of PPV23 in a lifetime for revaccination of patients, and for those between the age of 12 months and 18 years who have previously received two doses of the primary course of PCV10.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PPV23 vaccine includes antigens of 23 different serotypes of <i>S. pneumoniae</i>, which are responsible for more than 90% of cases of invasive pneumococcal (<a href=""https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease"" target=""_blank"">WHO 2003</a>). The Subcommittee noted that the recommended dosage of PPV23 is a single 0.5 mL dose of Pneumovax 23 subcutaneously or intramuscularly.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following evidence relating to the use of PPV23 in the prevention of pneumococcal disease in the 65–80-year age group:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31005428/"" target=""_blank"">Kim et al. Vaccine. 2019;37:2797-804</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28126327/"" target=""_blank"">Suzuki et al. Lancet Infect Dis. 2017;17:313-21</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/16941367/"" target=""_blank"">Vila-Corcoles et al. Clin Infect Dis. 2006;43:860-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20211953/"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24613522/"" target=""_blank"">Wiemken et al. Vaccine. 2014;32(19):2198-203</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24532544/"" target=""_blank"">Ochpa-Gondar et al. Clin Infect Dis. 2014;58:909-17</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23440780/"" target=""_blank"">Moberly et al. Cochrane Database Syst Rev 2013:CD000422</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28061505/"" target=""_blank"">Falkenhorst et al. PLoS One. 2017;12:e0169368</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.fhi.no/en/publ/2019/efficacy-and-effectiveness-of-pneumococcal-vaccination-in-adults---an-updat/#:~:text=We%20found%20both%20PPV23%20and,limited%20impact%20of%20waning%20immunity."" target=""_blank"">Winje et al. Norwegian Institute of Public Health. 2019</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32260132/"" target=""_blank"">Berild et al. Pathogens. 2020;9:259</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24484116/"" target=""_blank"">Menzies et al. Med J Aust. 2014;200:112-5</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26277073/"" target=""_blank"">Ahn et al. Vaccine. 2015; 33:4770-4775</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.bmj.com/content/340/bmj.c1004"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28542347/"" target=""_blank"">Htar et al. PLoS One. 2017;12:e0177985</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27846277/"" target=""_blank"">Baldo et al. PLoS One. 2016;11:e0166637</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26761816/"" target=""_blank"">Schiffner-Rohe et al. PLoS One. 2016;11:e0146338</a></p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that since PPVs stimulate a T-cell independent immune response, in contrast to PCVs, which stimulate T-cell memory response, PCV13 may have to be given in conjunction with PPV23 in order to achieve a benefit in the 65 year and over population.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted and agreed with PTAC’s consideration that there is a lack of evidence of effect for preventing non-bacteraemic pneumococcal pneumonia, a lack of evidence that PPV23 would reduce inequity in the Māori and Pacific population, there is insufficient data regarding the use of PPV23 in people between the ages of 60 and 65, that estimates of beneficial effect were wide and imprecise, and that the addition of conjugate pneumococcal vaccine 13-valent (PCV13) is likely needed prior to receiving PPV23 for patients to receive any measurable benefit.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for pneumococcal 23-valent vaccine if it were to be funded in New Zealand for people aged over 65 years<span style=""font-size: 8pt;"">.</span> This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000Heygg&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001lgs8"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: rgb(62, 62, 60);"">The Subcommittee considered a supplier application for 23 valent pneumococcal polysaccharide vaccine (PPV23) for the immunisation of people 65 to 80 years of age who have not received vaccination within 5 years (and were not &gt;65 years of age at the time of prior vaccination).\xa0\xa0</span></p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: rgb(62, 62, 60);"">The Subcommittee considered a supplier application for 23 valent pneumococcal polysaccharide vaccine (PPV23) for the immunisation of people 65 to 80 years of age who have not received vaccination within 5 years (and were not &gt;65 years of age at the time of prior vaccination).\xa0\xa0</span></p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2021', 'fs': 'Dec 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Immunisation Subcommittee at meeting Tuesday 10 August 2021.', 'fs': 'Clinical advice received from Immunisation Subcommittee at meeting Tuesday 10 August 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygg2AB'}, 'Id': 'a0POZ00000Heygg2AB', 'Event_Date__c': '2021-12-22', 'Event_Description__c': 'Clinical advice received from Immunisation Subcommittee at meeting Tuesday 10 August 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Dec 2021', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended </b>that the 23 valent pneumococcal polysaccharide vaccine for people over the age of 65 be <b>declined</b>.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered:</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the low-quality evidence and imprecise results for the efficacy of PPV23 against non-bacteraemic pneumococcal pneumonia;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>inconclusive evidence of efficacy against PPV23 serotypes and invasive pneumococcal disease (IPD);</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the lack of evidence for benefit for the Māori and Pacific populations;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the lack of data in people over the age of 60 who had risk factors other than hospitalisation;</p><p class=""ql-indent-1""><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>that the addition of conjugate pneumococcal vaccine 13-valent (PCV13) is likely needed prior to receiving PPV23 for patients to receive any measurable benefit.\xa0</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: rgb(62, 62, 60);"">The Subcommittee considered a supplier application for 23 valent pneumococcal polysaccharide vaccine (PPV23) for the immunisation of people 65 to 80 years of age who have not received vaccination within 5 years (and were not &gt;65 years of age at the time of prior vaccination).\xa0\xa0</span></p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PPV23 has been previously considered by both PTAC and the Immunisation Subcommittee on multiple occasions:</p><p class=""ql-indent-1"">1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">February 2014</a> where an application for people aged 65 years and over was recommended for decline;</p><p class=""ql-indent-1"">1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By The Immunisation Subcommittee in <a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-minutes-2015-02-18.pdf"" target=""_blank"">February 2015</a> where no formal recommendation was given;</p><p class=""ql-indent-1"">1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>By PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-08.pdf"" target=""_blank"">August 2015</a> where an application for people aged 65 years and over was recommended for decline.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application was most recently reviewed by PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2021-03.pdf"" target=""_blank"">March 2021</a>, where it was again recommended for decline. The Subcommittee noted that PTAC considered the evidence for PPV23 against pneumococcal infection in those aged over 65 to be of poor quality and mixed strength, with low-moderate, inconclusive evidence of efficacy against PPV23 serotypes and invasive pneumococcal disease (IPD), and low-quality evidence and imprecise results for the efficacy of PPV23 against non-bacteraemic pneumococcal pneumonia (NBPP). PTAC also noted that effectiveness was not demonstrated to be consistent in the general population, and that the meta-analyses reported a wide range of effectiveness estimates. The Subcommittee noted PTAC’s past advice was that PPV23 is effective against IPD, and that more robust evidence is needed to show efficacy against NBPP. PTAC also considered that the evidence presented for PPV23 against NBPP is imprecise and of low quality. The Subcommittee noted that PTAC considered that although there appears to be limited benefit with PPV23, there would be no additional clinical risk to widening access, and no non-clinical features of the vaccine that would impact on its use by healthcare workers that are different to other vaccines. The Subcommittee noted and agreed with PTAC’s considerations and recommendation.\xa0</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that pneumococcal infection is a common disease that affects all age groups and has the potential to cause significant illness, sometimes leading to hospitalisation or death. The Subcommittee noted that in 2019 the rate of invasive pneumococcal disease was 25 per 100,000 population for those aged 65-80 years, and that Māori and Pacific people are overrepresented, with rates of 37.0 and 28.9 per 100,000, respectively. The Subcommittee noted that <i>S. pneumoniae </i>is the underlying pathogen in 30-50% of cases of NBPP. The Subcommittee noted 16 people aged 65 or over died in 2018 as a result of pneumococcal infection. The Subcommittee noted that any herd immunity effects from the childhood pneumococcal vaccination programme has not reduced the pneumococcal related mortality rates in the over 65-year age group.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PPV23 vaccine is currently funded on the Pharmaceutical Schedule for vaccination of adults aged 18 years and older with HIV infection; who are pre- or post-HSCT or chemotherapy; who are pre- or post-splenectomy or with functional asplenia; who are pre- or post-solid organ transplant; undergoing renal dialysis; with complement deficiency (acquired or inherited); with cochlear implants; with primary immunodeficiency. The Subcommittee noted that Pharmac also funds one dose of pneumococcal conjugate vaccine (PCV13) for people with chronic conditions who are at higher risk of pneumococcal infection with a maximum of three doses of PPV23 in a lifetime for revaccination of patients, and for those between the age of 12 months and 18 years who have previously received two doses of the primary course of PCV10.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the PPV23 vaccine includes antigens of 23 different serotypes of <i>S. pneumoniae</i>, which are responsible for more than 90% of cases of invasive pneumococcal (<a href=""https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease"" target=""_blank"">WHO 2003</a>). The Subcommittee noted that the recommended dosage of PPV23 is a single 0.5 mL dose of Pneumovax 23 subcutaneously or intramuscularly.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following evidence relating to the use of PPV23 in the prevention of pneumococcal disease in the 65–80-year age group:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31005428/"" target=""_blank"">Kim et al. Vaccine. 2019;37:2797-804</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28126327/"" target=""_blank"">Suzuki et al. Lancet Infect Dis. 2017;17:313-21</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/16941367/"" target=""_blank"">Vila-Corcoles et al. Clin Infect Dis. 2006;43:860-8</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/20211953/"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24613522/"" target=""_blank"">Wiemken et al. Vaccine. 2014;32(19):2198-203</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24532544/"" target=""_blank"">Ochpa-Gondar et al. Clin Infect Dis. 2014;58:909-17</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/23440780/"" target=""_blank"">Moberly et al. Cochrane Database Syst Rev 2013:CD000422</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28061505/"" target=""_blank"">Falkenhorst et al. PLoS One. 2017;12:e0169368</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.fhi.no/en/publ/2019/efficacy-and-effectiveness-of-pneumococcal-vaccination-in-adults---an-updat/#:~:text=We%20found%20both%20PPV23%20and,limited%20impact%20of%20waning%20immunity."" target=""_blank"">Winje et al. Norwegian Institute of Public Health. 2019</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32260132/"" target=""_blank"">Berild et al. Pathogens. 2020;9:259</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/24484116/"" target=""_blank"">Menzies et al. Med J Aust. 2014;200:112-5</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26277073/"" target=""_blank"">Ahn et al. Vaccine. 2015; 33:4770-4775</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.bmj.com/content/340/bmj.c1004"" target=""_blank"">Maruyama et al. BMJ. 2010;340:c1004</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28542347/"" target=""_blank"">Htar et al. PLoS One. 2017;12:e0177985</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27846277/"" target=""_blank"">Baldo et al. PLoS One. 2016;11:e0166637</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26761816/"" target=""_blank"">Schiffner-Rohe et al. PLoS One. 2016;11:e0146338</a></p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that since PPVs stimulate a T-cell independent immune response, in contrast to PCVs, which stimulate T-cell memory response, PCV13 may have to be given in conjunction with PPV23 in order to achieve a benefit in the 65 year and over population.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted and agreed with PTAC’s consideration that there is a lack of evidence of effect for preventing non-bacteraemic pneumococcal pneumonia, a lack of evidence that PPV23 would reduce inequity in the Māori and Pacific population, there is insufficient data regarding the use of PPV23 in people between the ages of 60 and 65, that estimates of beneficial effect were wide and imprecise, and that the addition of conjugate pneumococcal vaccine 13-valent (PCV13) is likely needed prior to receiving PPV23 for patients to receive any measurable benefit.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for pneumococcal 23-valent vaccine if it were to be funded in New Zealand for people aged over 65 years<span style=""font-size: 8pt;"">.</span> This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000Heygg&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001lgs8"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000DRGvQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2024', 'fs': 'Aug 2024', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygm2AB'}, 'Id': 'a0POZ00000Heygm2AB', 'Event_Date__c': '2024-08-07', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2024', 'Status_History__c': 'a13OZ00000D1IMpYAN'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2024', 'fs': 'Aug 2024', 'change': None}, 'Event_Description': {'s': 'Assigned to Immunisation Advisory Committee meeting to provide advice on Thursday 5 September 2024', 'fs': 'Assigned to Immunisation Advisory Committee meeting to provide advice on Thursday 5 September 2024', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygn2AB'}, 'Id': 'a0POZ00000Heygn2AB', 'Event_Date__c': '2024-08-22', 'Event_Description__c': 'Assigned to Immunisation Advisory Committee meeting to provide advice on Thursday 5 September 2024', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2024', 'Status_History__c': 'a13OZ00000END34YAH'}, 'change': None}, {'Summary': {'s': '<p>The Immunisation Advisory Committee recommended that the current PPV23 pneumococcal polysaccharide vaccine for people aged 65 years and above be <strong>declined </strong>for funding.\xa0</p>', 'fs': '<p>The Immunisation Advisory Committee recommended that the current PPV23 pneumococcal polysaccharide vaccine for people aged 65 years and above be <strong>declined </strong>for funding.\xa0</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2024-09-05-Immunisation-Advisory-Committee-Meeting.pdf#page=37"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2024-09-05-Immunisation-Advisory-Committee-Meeting.pdf#page=37"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jan 2025', 'fs': 'Jan 2025', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Immunisation Advisory Committee at meeting Thursday 5 September 2024.', 'fs': 'Clinical advice received from Immunisation Advisory Committee at meeting Thursday 5 September 2024.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygo2AB'}, 'Id': 'a0POZ00000Heygo2AB', 'Event_Date__c': '2025-01-31', 'Event_Description__c': 'Clinical advice received from Immunisation Advisory Committee at meeting Thursday 5 September 2024.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2024-09-05-Immunisation-Advisory-Committee-Meeting.pdf#page=37"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'Outcome__c': 'Decline', 'Summary__c': '<p>The Immunisation Advisory Committee recommended that the current PPV23 pneumococcal polysaccharide vaccine for people aged 65 years and above be <strong>declined </strong>for funding.\xa0</p>', 'Formatted_Date__c': 'Jan 2025', 'Status_History__c': 'a13OZ00000JW7QAYA1'}, 'change': None}]",Feb 2014,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2014', 'fs': 'Feb 2014', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000HeygX2AR'}, 'Id': 'a0POZ00000HeygX2AR', 'Event_Date__c': '2014-02-14', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2014', 'Status_History__c': 'a132P000000AqbuQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2022', 'fs': 'Jan 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygh2AB'}, 'Id': 'a0POZ00000Heygh2AB', 'Event_Date__c': '2022-01-21', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jan 2022', 'Status_History__c': 'a132P000000DUNuQAO'}, 'change': None}]",Feb 2014,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2014', 'fs': 'May 2014', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000HeygY2AR'}, 'Id': 'a0POZ00000HeygY2AR', 'Event_Date__c': '2014-05-27', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'May 2014', 'Status_History__c': 'a132P000000AqhZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygi2AB'}, 'Id': 'a0POZ00000Heygi2AB', 'Event_Date__c': '2022-03-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DaQCQA0'}, 'change': None}]",May 2014,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygj2AB'}, 'Id': 'a0POZ00000Heygj2AB', 'Event_Date__c': '2023-12-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004kjClYAI'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygk2AB'}, 'Id': 'a0POZ00000Heygk2AB', 'Event_Date__c': '2024-02-12', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000006lrNGYAY'}, 'change': None}]",Feb 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Heygl2AB'}, 'Id': 'a0POZ00000Heygl2AB', 'Event_Date__c': '2024-07-29', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000CgBRcYAN'}, 'change': None}]",Jul 2024,False,True
